[Biojava-dev] CHI's GPCRs & Protein Kinase Targets Conferences

support at biotaq.com support at biotaq.com
Mon Apr 28 23:24:55 EDT 2003


********************************************************
to unsubscribe, simply reply to this email, thanks.
********************************************************

May 2, 2003 Advance registration deadline

Cambridge Healthtech Institute’s (CHI)

GPCRs
>From Orphan to Blockbuster
Conference: June 9-10, 2003
Westin Copley Place Hotel
Boston, Massachusetts

Protein Kinase Targets
Strategies for Drug Development
Conference: June 10-11, 2003
Westin Copley Place Hotel
Boston, Massachusetts

Download PDF of GPCR Here:
http://www.healthtech.com/2003/gpc/pdf.asp

Download PDF of Kinase Here:
http://www.healthtech.com/2003/kin/pdf.asp

GPCRs

More than 70% of the drugs on the market today are targeted to GPCRs, with
sales of more than $30 billion. These targets will continue to be key in
the search for effective therapeutics. This premier conference will
address the important issues of GPCRs as targets and therapeutics and will
present problem-solving strategies in the search for more effective
GPCR-targeted drug discovery.

This conference will feature insights and coverage of:

Structure  -  Targets  -  Drug Discovery  -  Screening

Register for GPCR Here:
http://www.healthtech.com/2003/gpc/reg.asp

Protein Kinase Targets

Protein kinases play an essential role in many signaling pathways, and
therefore have the potential to contribute to diseases ranging from cancer
and inflammation to diabetes and cardiovascular disorders, not to mention
cell growth, survival and many other biological functions. Recent
investigations reveal that there are over 500 human kinases, making them
the most populated class of druggable targets. Identification of kinase
specificity and functional validation of kinase as targets has been a
challenge, but innovative approaches have been developed to address these
issues.This conference provides useful insight into strategies that are
being employed in structure-based design and screening approaches, as well
as questions of compound selectivity between kinases. A session devoted to
the development of non-ATP competitive kinase inhibitors will also be
featured. Case studies of drug development will provide additional lessons
that will aid the audience in their research efforts.

This conference will feature insights and coverage of:

Functional Understanding of Kinases  -  Structure-Based Design
trategies  -  Screening Strategies  -  Indication-Specific Kinase
Applications  -  Novel Binding Sites for Kinases

Register for Kinase Here:
http://www.healthtech.com/2003/gpc/reg.asp


FIVE WAYS TO REGISTER:
• web: www.healthtech.com • phone: 617-630-1300 • toll-free in the U.S.:
888-999-6288
• fax: 617-630-1325 • email: chi at healthtech.com • mail: Cambridge
Healthtech Institute, 1037 Chestnut Street, Newton Upper Falls, MA 02464
USA
********************************************************
This segmented email list tends to serve the people who are
interested in news and product info in Proteomics sector. To
unsubscribe, simply reply to this email.

To distribute your releases to this list, contact sales at biotaq.com.

To order market report "Cancer Immunotherapy Beyond Monoclonals"
from Biotaq.com at:

http://www.biotaq.com/onsale/biotaqreports.htm

BIOTAQ.COM's email Newswire service is focused exclusively on biotech
industry. Edit or change your interest category selections at:

https://www.biotaq.com/interests.htm
**************************************************************************
**



More information about the biojava-dev mailing list